Introduction
The combination of fosnetupitant chloride hydrochloride and palonosetron hydrochloride, commonly known as AKYNZEO®, has revolutionized the treatment of chemotherapy-induced nausea and vomiting (CINV). This article delves into the market dynamics, financial trajectory, and key factors influencing the growth of this drug combination.
Mechanism of Action
Fosnetupitant, a water-soluble phosphorylated pro-drug of netupitant, rapidly converts to netupitant in vivo, which selectively antagonizes human substance P/NK1 receptors. Palonosetron, on the other hand, is a selective 5-HT3 receptor antagonist with a strong binding affinity for this receptor. Together, they target two critical pathways associated with acute and delayed CINV, providing comprehensive antiemetic coverage[4].
Market Size and Growth
The global netupitant–palonosetron FDC market, which includes AKYNZEO®, has seen significant growth. In 2015, the market was valued at $257,162 million and is estimated to reach $527,187 million by 2022, growing at a CAGR of 10.8% during the forecast period. This growth is driven by the increasing number of patients undergoing chemotherapy and the need for more effective antiemetic treatments[1].
Geographic Segmentation
Geographically, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA. North America has been the dominant regional market due to the high incidence of CINV among patients, followed by Europe. The approval of new drugs such as rolapitant and Sustol in the US market has further boosted the growth in these regions[1].
Patient Pool and Adoption
The patient pool segment has witnessed large-scale adoption of netupitant-palonosetron FDC drugs. The rise in the number of patients undergoing chemotherapy and the introduction of novel delivery methods to improve patient compliance have contributed to this adoption. The efficacy of combination therapy, particularly in treating highly emetogenic cytotoxic drugs, has been a key driver[1].
Technological Advancements
Technological advancements play a crucial role in the market growth. Companies are seeking new technologies to lower production costs and discover new products. For instance, the development of rolapitant (Varubi) by Tesaro has gained significant traction in the CINV drugs segment. Similarly, the introduction of needle-free, painless, and cost-effective transdermal drug delivery systems is expected to increase demand[1].
Competitive Landscape
The market is competitive, with major players such as Helsinn Holding S.A., Heron Therapeutics, Inc., and Eisai Pharmaceutical Pvt Ltd. These companies are adopting strategies to sustain a competitive environment and increase their market share. Helsinn, for example, has a strong focus on oncology and rare diseases, with over forty years of commercial execution[1][5].
Financial Impact and Healthcare Costs
Real-world evidence published in the journal Advances in Therapy has shown that AKYNZEO® (fosnetupitant with palonosetron) has a positive impact on treatment outcomes and healthcare costs. The data indicates that the use of AKYNZEO® can lead to better patient outcomes and reduced healthcare costs associated with CINV management[5].
Market Segmentation
The market is segmented based on patient pool type and geography. The palonosetron hydrochloride market is also categorized by application (injection, oral capsule) and product purity (≥98%, ≥99%). These segmentations help in understanding the diverse market dynamics and opportunities[1][2].
Drivers and Restraints
Key drivers of the market include the increasing incidence of CINV, the need for more effective antiemetic treatments, and technological advancements in drug delivery systems. However, factors such as variability in genes encoding enzymes and proteins related to antiemetic drugs, which can lead to suboptimal response rates, act as restraints. Additionally, the high production costs and regulatory hurdles can also impact market growth[1].
Future Outlook
The palonosetron hydrochloride market is expected to continue its growth trajectory from 2023 to 2031, with a CAGR of 3 to 5%. The comprehensive assessment of market dynamics, including drivers, restraints, opportunities, and challenges, indicates a consistent upward trend in market growth. The introduction of new delivery methods and the approval of new drugs will further drive this growth[2].
Key Takeaways
- The global netupitant–palonosetron FDC market is projected to grow significantly, driven by the increasing incidence of CINV and the need for effective treatments.
- Technological advancements and novel delivery methods are key drivers of market growth.
- Geographic segmentation shows North America and Europe as dominant markets.
- Major players are adopting competitive strategies to increase market share.
- Real-world evidence indicates positive impacts on treatment outcomes and healthcare costs.
FAQs
What is the mechanism of action of fosnetupitant and palonosetron?
Fosnetupitant converts to netupitant, which antagonizes human substance P/NK1 receptors, while palonosetron is a selective 5-HT3 receptor antagonist, together targeting pathways associated with CINV[4].
Which regions dominate the netupitant–palonosetron FDC market?
North America and Europe are the dominant regional markets due to the high incidence of CINV among patients[1].
What are the key drivers of the netupitant–palonosetron FDC market?
Key drivers include the increasing incidence of CINV, the need for more effective antiemetic treatments, and technological advancements in drug delivery systems[1].
How does AKYNZEO® impact healthcare costs?
Real-world evidence indicates that AKYNZEO® leads to better patient outcomes and reduced healthcare costs associated with CINV management[5].
What is the projected growth rate of the palonosetron hydrochloride market?
The palonosetron hydrochloride market is expected to grow at a CAGR of 3 to 5% from 2023 to 2031[2].
Sources
- Allied Market Research - Netupitant – Palonosetron FDC Market Size - Analysis 2022
- Market Research Intellect - Palonosetron Hydrochloride Market Size and Forecast
- Market Research Intellect - Palonosetron Hydrochloride Injection Market Size, Scope And Forecast
- Australian Government Department of Health - Australian public assessment report for Fosnetupitant (as chloride) hydrochloride - Palonosetron hydrochloride
- BioSpace - Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs
